BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
Breaking News: Topic alerts now available for all BioWorld subscribers
See today's BioWorld Science
Home
» SJ-3149, a selective CK1α degrader with activity across a range of hematologic and solid tumors
To read the full story,
subscribe
or
sign in
.
Cancer
SJ-3149, a selective CK1α degrader with activity across a range of hematologic and solid tumors
Jan. 22, 2024
No Comments
Researchers from St. Jude Children’s Research Hospital have reported the discovery of SJ-3149, a novel selective CK1α degrader being developed for the treatment of cancer.
BioWorld Science
New compound
Cancer
